Cozaar drug classification
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Cozaar Drug Classification
Angiotensin II Receptor Antagonist
Cozaar, known generically as losartan, is classified as an angiotensin II receptor antagonist, specifically targeting the angiotensin II type 1 (AT1) receptor. This classification places it within a group of medications that are used primarily for their antihypertensive properties. Losartan works by blocking the action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and improving cardiovascular outcomes .
Pharmacokinetics and Metabolism
Losartan is well-absorbed orally and undergoes rapid conversion in the liver to its more potent metabolite, E3174. This metabolite has a significantly higher affinity for the AT1 receptor, contributing to the drug's efficacy. The half-life of E3174 ranges from 6 to 9 hours, and the drug is eliminated through both renal and hepatic routes. This pharmacokinetic profile supports once-daily dosing, which is effective in managing hypertension and heart failure.
Clinical Applications
Hypertension
Losartan is widely used in the management of hypertension. Its ability to block the AT1 receptor helps in reducing blood pressure, making it a first-line treatment option for many patients. Over 6 million patients have been treated with losartan for hypertension, demonstrating its efficacy and tolerability .
Heart Failure
In addition to hypertension, losartan is also used in the treatment of heart failure. Clinical studies have shown that losartan can improve survival rates in heart failure patients, making it a valuable option in this patient population. The drug's hemodynamic activity over a 24-hour period with once-daily dosing is particularly beneficial for heart failure management.
Comparative Studies
Bioequivalence
A study comparing the bioequivalence of two formulations of losartan, LOSARDIL 100™ and COZAAR™, found that both formulations are bioequivalent in terms of absorption. This means that the generic version, LOSARDIL 100™, can be considered as effective as the branded COZAAR™ for clinical use. The study measured various pharmacokinetic parameters, including Cmax, Tmax, and AUC, and found no significant differences between the two formulations.
Conclusion
Cozaar (losartan) is a well-established angiotensin II receptor antagonist used primarily for the treatment of hypertension and heart failure. Its pharmacokinetic properties, including rapid conversion to a potent metabolite and effective once-daily dosing, make it a reliable option for long-term management of these conditions. Clinical studies and bioequivalence research further support its efficacy and safety, solidifying its role in cardiovascular therapy.
Sources and full results
Most relevant research papers on this topic